A Phase II Study of a Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia (ALL) Incorporating Inotuzumab Ozogamicin (InO)
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Inotuzumab ozogamicin (Primary) ; Dasatinib; Dexamethasone; Dexamethasone; Methotrexate; Ponatinib; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 01 Aug 2024 Planned End Date changed from 1 May 2026 to 1 Mar 2025.
- 01 Aug 2024 Planned primary completion date changed from 30 Jun 2024 to 1 Mar 2025.
- 24 Aug 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.